SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.
In addition, Dr. Damaj is scheduled to present at the See Thru Equity Fall Microcap Investor Conference to be held at the Convene in New York, New York on September 11, 2014. The presentation will take place on September 11th 2014 at 10AM EDT. In addition, management will be present at the StockVest booth to meet with investors and analysts.
The Company's investor presentation will include the following:
- Overview of the Company's business model;
- Details on the Company's commercial efforts;
- Update on the two newly signed partnerships;
- Overview of its four commercial products; and
- Management expertise and profile.
The presentation will be available at the Company's website at www.innovuspharma.com
Members of the investment community interested in meeting with management that day can contact their representative at SeeThruEquity, or Art Brent of StockVest at Art@StockVest.com.
In addition, Innovus Pharma is pleased to have been selected to be featured in the upcoming edition of the StockVest Newsletter, a leading financial market related magazine focused on micro-cap stocks. Each issue features educational content, news of interest to the investment community, information on upcoming events along with timely and relevant articles of interest to investors. The StockVest newsletter featuring Innovus will be distributed to investors at the upcoming Rodman & Renshaw conference in New York September 9 and 10 2014 (www.rodm.com) as well as the National Investment Banking Association Conference September 16 and 17 2014 (www.nibanet.org).
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including Sensum+™ (for sales outside the U.S. only) and Zestra® Glide.
For more information, go to www.innovuspharma.com; www.zestra.com and www.ejectdelay.com
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra®, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.